JW Pharmaceutical (KOSPI 001060) 2026 stock analysis: the high-barrier basic IV-fluid business, cash-cow prescription drugs like Livalo, a Wnt-targeting oncology pipeline, JW Holdings governance, drug-pricing regulation risk, and dividends — for investors accessing KOSPI directly.
A qualitative 2026 outlook on Chong Kun Dang (KRX: 185750), the Korean pharma whose K-CAB-led incremental drugs fund a diversifying novel-drug pipeline. We unpack the cash-cow base, licensing-out and royalty optionality, operating margins and R&D, drug-price pressure, peer positioning, and what global investors should monitor each quarter.
Merck (MRK) 2026 stock analysis: Keytruda's 2028 patent cliff, Winrevair growth, $112.30 price, 3% dividend, analyst targets, and US investor tax strategy.
Pfizer (PFE) 2026 stock analysis: $26.48 price, 6.5% dividend yield, Seagen pipeline, patent cliff risks, and 12-month price targets for US investors.